Stefanie Luecke

Stefanie Luecke

Auto-generated profile, based on publicly available information

Stefanie Luecke

Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, Los Angeles, California, United States of America

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2017 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
SLStefanie Luecke
Stefanie Luecke
AHAndreas Holleufer
Andreas Holleufer
MCMaria H Christensen
Maria H Christensen
KJKasper L Jønsson
Kasper L Jønsson
GBGerardo A Boni
Gerardo A Boni
SPSøren R Paludan
Søren R Paludan

27 May 2016 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
MCMaria H Christensen
Maria H Christensen
SJSøren B Jensen
Søren B Jensen
Juho MiettinenJuho Miettinen
Juho Miettinen
SLStefanie Luecke
Stefanie Luecke
TPThaneas Prabakaran
Thaneas Prabakaran
SPSøren R Paludan
Søren R Paludan

7 August 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BOBenson Ogunjimi
Benson Ogunjimi
SZShen-Ying Zhang
Shen-Ying Zhang
KSKatrine B. Sørensen
Katrine B. Sørensen
KSKristian A. Skipper
Kristian A. Skipper
MCMadalina Elena Carter-Timofte
Madalina Elena Carter-Timofte
TMTrine H. Mogensen
Trine H. Mogensen
Varicella zoster virus (VZV) typically causes chickenpox upon primary infection. In rare cases, VZV can give rise to life-threatening disease in otherwise healthy people, but the immunological basis for this remains unexplained. We report 4 cases of acute severe VZV infection affecting the central nervous system or the lungs in unrelated, otherwise healthy children who are heterozygous for rare missense mutations in POLR3A (one patient), POLR3C (one patient), or both (two patients). POLR3A and POLR3C encode subunits of RNA polymerase III. Leukocytes from all 4 patients tested exhibited poor IFN induction in response to synthetic or VZV-derived DNA. Moreover, leukocytes from 3 of the patients displayed defective IFN production upon VZV infection and reduced control of VZV replication. These phenotypes were rescued by transduction with relevant WT alleles. This work demonstrates that monogenic or digenic POLR3A and POLR3C deficiencies confer increased susceptibility to severe VZV disease in otherwise healthy children, providing evidence for an essential role of a DNA sensor in human immunity.

2 April 2016 in OncoImmunology
Verified
Journal Article
Open access
GCGuranda Chitadze
Guranda Chitadze
MLMarcus Lettau
Marcus Lettau
SLStefanie Luecke
Stefanie Luecke
TWTing Wang
Ting Wang
OJOttmar Janssen
Ottmar Janssen
Dieter KabelitzDieter Kabelitz
Dieter Kabelitz
The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) and UL-16 binding protein (ULBP) family members expressed on tumor cells with the corresponding NKG2D receptor triggers cytotoxic effector functions in NK cells and γδ T cells. However, as a mechanism of tumor immune escape, NKG2D ligands (NKG2DLs) can be released from the cell surface. In this study, we investigated the NKG2DL system in different human glioblastoma (GBM) cell lines, the most lethal brain tumor in adults. Flow cytometric analysis and ELISA revealed that despite the expression of various NKG2DLs only ULBP2 is released as a soluble protein via the proteolytic activity of “a disintegrin and metalloproteases” (ADAM) 10 and 17. Moreover, we report that temozolomide (TMZ), a chemotherapeutic agent in clinical use for the treatment of GBM, increases the cell surface expression of NKG2DLs and sensitizes GBM cells to γδ T cell-mediated lysis. Both NKG2D and the T-cell receptor (TCR) are involved. The cytotoxic activity of γδ T cells toward GBM cells is strongly enhanced in a TCR-dependent manner by stimulation with pyrophosphate antigens. These data clearly demonstrate the complexity of mechanisms regulating NKG2DL expression in GBM cells and further show that treatment with TMZ can increase the immunogenicity of GBM. Thus, TMZ might enhance the potential of the adoptive transfer of ex vivo expanded γδ T cells for the treatment of malignant glioblastoma.

8 August 2017 in OncoImmunology
Verified
Journal Article
Closed access
GCGuranda Chitadze
Guranda Chitadze
CFCharlotte Flüh
Charlotte Flüh
EQElgar Susanne Quabius
Elgar Susanne Quabius
SFSandra Freitag-Wolf
Sandra Freitag-Wolf
CPChristian Peters
Christian Peters
Dieter KabelitzDieter Kabelitz
Dieter Kabelitz
Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy. Immunological mechanisms including the Natural Killer Group 2 member D (NKG2D) receptor-ligand system play an important role in tumor immune surveillance and targeting the NKG2D system might be beneficial. However, before considering any kind of immunotherapy, a precise characterization of the immune system is important, particularly in GBM patients where conventional therapies with impact on the immune system are frequently co-administered. Here we performed an in-depth immunophenotyping of GBM patients and age-matched healthy controls and analyzed NKG2D ligand expression on primary GBM cells ex vivo. We report that GBM patients have a compromised innate immune system irrespective of steroid (dexamethasone) medication. However, dexamethasone drastically reduced the number of immune cells in the blood of GBM patients. Moreover, higher counts of immune cells influenced by dexamethasone like CD45+ lymphocytes and non-Vδ2 γδ T cells were associated with better overall survival. Higher levels of NKG2D ligands on primary GBM tumor cells were observed in patients who received radiochemotherapy, pointing towards increased immunogenic potential of GBM cells following standard radiochemotherapy. This study sheds light on how steroids and radiochemotherapy affect immune cell parameters of GBM patients, a pre-requisite for the development of new therapeutic strategies targeting the immune system in these patients.